Reproductive Epidemiology

Associate Professor Lisa Hui from Department of Obstetrics & Gynaecology has been promoted  to co-group leader of the Reproductive Epidemiology group at the MCRI in recognition of her research contributions and leadership qualities.

Associate Professor Lisa Hui has been an honorary researcher in the group since 2015, and team leader since 2018, improving its productivity and translational impact through her national and international leadership roles in maternal fetal medicine.

The Reproductive Epidemiology group was founded by Professor Jane Halliday AM, with a vision to measure, monitor and maximise childhood health outcomes associated with developmental exposures.  The group’s two main objectives are to:

1) To understand the impact of in utero exposures on health and wellbeing of infants, children, and young adults, integrating knowledge of genetics, epigenetics, maternal fetal medicine and environmental and psychosocial risk factors.

2) To close the critical knowledge gaps in the rapidly advancing field of prenatal diagnosis by providing high quality, population-based data for assessing disease
prevalence, trends in clinical practice, screening program evaluation and childhood outcomes.

A/Prof Lisa Hui’s research interests and collaborations are closely connected with that of the MCRI. Her extensive co-authorship group and successful grants show the natural synergies between her background in maternal fetal medicine and the research priorities and values of the MCRI.

Lisa’s contribution to current externally funded MCRI projects include:

* CIA on an NHMRC cohort study (Childhood outcomes of prenatal genomic copy number variants: the prenatal microarray cohort study, 2020-2023)
* CIC on the ARC linkage project between VCGS, Illumina, and Monash University (Societal, Ethical and Legal implications of Non-invasive Prenatal Testing; CIA Prof Catherine Mills, 2021-2024).
* CII on the NHMRC Cohort study on newborn screening for congenital cytyomegalovirus infection (Whole-of-population CRISPR point-of-care testing for congenital cytomegalovirus to prevent hearing and neurodevelopment disabilities through a public health approach; CIA Valerie Sung, 2021-2025).